Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 10;384(23):2259-2261.
doi: 10.1056/NEJMc2103916. Epub 2021 Apr 6.

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Nicole Doria-Rose  1 , Mehul S Suthar  2 , Mat Makowski  3 , Sarah O'Connell  4 , Adrian B McDermott  4 , Britta Flach  4 , Julie E Ledgerwood  4 , John R Mascola  4 , Barney S Graham  4 , Bob C Lin  4 , Sijy O'Dell  4 , Stephen D Schmidt  4 , Alicia T Widge  4 , Venkata-Viswanadh Edara  5 , Evan J Anderson  5 , Lilin Lai  5 , Katharine Floyd  5 , Nadine G Rouphael  5 , Veronika Zarnitsyna  5 , Paul C Roberts  4 , Mamodikoe Makhene  4 , Wendy Buchanan  4 , Catherine J Luke  4 , John H Beigel  4 , Lisa A Jackson  6 , Kathleen M Neuzil  7 , Hamilton Bennett  8 , Brett Leav  8 , Jim Albert  3 , Pratap Kunwar  3 ; mRNA-1273 Study Group
Collaborators, Affiliations

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Nicole Doria-Rose et al. N Engl J Med. .

Erratum in

No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Time Course of SARS-CoV-2 Antibody Binding and Neutralization Responses after mRNA-1273 Vaccination.
All the participants received 100 μg of mRNA-1273 on days 1 and 29, indicated by arrows. The numbers of participants in each age group with data available at day 209 are as follows: 18 to 55 years, 15 participants; 56 to 70 years, 9 participants; and 71 years or older, 9 participants. The titers shown are the binding to spike receptor–binding domain protein (the end-point dilution titer) assessed on enzyme-linked immunosorbent assay (ELISA) on days 1, 15, 29, 36, 43, 57, 119, and 209 (Panel A); the 50% inhibitory dilution (ID50) titer on pseudovirus neutralization assay on days 1, 15, 29, 36, 43, 57, 119, and 209 (Panel B); and the ID50 titer on the live-virus focus-reduction neutralization mNeonGreen test (FRNT-mNG) on days 1, 29, 43, 119, and 209 (Panel C). Lines show geometric mean titers for each age group; 𝙸 bars indicate 95% confidence intervals. The dashed line indicates the limit of detection for each assay.
See this image and copyright information in PMC

Similar articles

  • Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
    Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Buchanan W, Luke CJ, Ledgerwood JE, Mascola JR, Graham BS, Beigel JH; mRNA-1273 Study Group. Widge AT, et al. N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3. N Engl J Med. 2021. PMID: 33270381 Free PMC article. No abstract available.
  • Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
    Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, Colpitts T, Bennett H, Boyoglu-Barnum S, Shi W, Moliva JI, Sullivan NJ, Graham BS, Carfi A, Corbett KS, Seder RA, Edwards DK. Wu K, et al. N Engl J Med. 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179. Epub 2021 Mar 17. N Engl J Med. 2021. PMID: 33730471 Free PMC article. Clinical Trial. No abstract available.
  • Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
    Wang Y. Wang Y. EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3. EBioMedicine. 2021. PMID: 34742128 Free PMC article. No abstract available.
  • Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
    Collier AY, McMahan K, Yu J, Tostanoski LH, Aguayo R, Ansel J, Chandrashekar A, Patel S, Apraku Bondzie E, Sellers D, Barrett J, Sanborn O, Wan H, Chang A, Anioke T, Nkolola J, Bradshaw C, Jacob-Dolan C, Feldman J, Gebre M, Borducchi EN, Liu J, Schmidt AG, Suscovich T, Linde C, Alter G, Hacker MR, Barouch DH. Collier AY, et al. JAMA. 2021 Jun 15;325(23):2370-2380. doi: 10.1001/jama.2021.7563. JAMA. 2021. PMID: 33983379 Free PMC article.
  • Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.
    Shen X, Tang H, Pajon R, Smith G, Glenn GM, Shi W, Korber B, Montefiori DC. Shen X, et al. N Engl J Med. 2021 Jun 17;384(24):2352-2354. doi: 10.1056/NEJMc2103740. Epub 2021 Apr 7. N Engl J Med. 2021. PMID: 33826819 Free PMC article. No abstract available.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-416. - PMC - PubMed
    1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med 2020;383:1920-1931. - PMC - PubMed
    1. Widge AT, Rouphael NG, Jackson LA, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med 2021;384:80-82. - PMC - PubMed
    1. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020;383:2427-2438. - PMC - PubMed
    1. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021;371(6529):eabf4063-eabf4063. - PMC - PubMed

Publication types